@instylla

Instylla is focused on developing next-generation liquid embolics for interventional radiology.

 Bedford, MA
instylla.com
Joined May 2021
  • Tweets98
  • Following97
  • Followers59
87Media
Catheter entrapment can happen when an embolic agent adheres to the catheter or vessel wall. Embrace® HES is non-adhesive. It eliminates the risk of catheter entrapment. Even if embedded, its properties allow for a smooth retrieval. #EmbraceHES #InterventionalRadiology
1
106
This Liver Cancer Awareness Month, we recognize the patients, caregivers, and clinicians who face this disease every day. At Instylla, they’re the reason we do what we do. #LiverCancerAwarenessMonth #LiverCancer #InterventionalRadiology #Octoberis4Livers
🤖 Made with AI
1
13
Thank you to everyone who joined us at #SEAS2026! And thank you to our speakers for sharing their early experience with Embrace® HES. We enjoyed connecting with all of you in Isle of Palms!
1
2
31
Now out on @_backtable: @kavikrishVIR, @Resmi_Charalel, @milanpatelMD walk through several cases and share their firsthand experience with Embrace HES. Sponsored by Instylla. #EmbraceHES #InterventionalRadiology backtable.com/shows/vi/podca…

Liquid Embolization Techniques for Treating Hypervascular Tumors | BackTable VI Podcast

Listen to the BackTable Vascular & Interventional Podcast on Liquid Embolization Techniques for Treating Hypervascular Tumors with Dr. Resmi Charalel, Dr. Milan Patel, Dr. Venkatesh Krishnasamy....

backtable.com
1
2
6
235
If you're attending SEAS, start your Thursday by hearing from five interventional radiologists as they share lessons, insights, and case reviews from their early experience with Embrace® HES. ☕ 📅 Tomorrow, Oct 8 | ⏰ 7:00 AM #SEAS2026 #Irad
1
44
We're headed to SEAS 2026 in Isle of Palms, SC! 🌴 Join us from October 7-10 to connect with our team and learn more about Embrace® HES We look forward to seeing you there! #SEAS2026 #InterventionalRadiology #Embolization #LiquidEmbolics #EmbraceHES
23
Join us for breakfast at SEAS! ☕ Five interventional radiologists will share their early experience with Embrace® HES, including lessons learned and real case reviews. "The Future of Liquid Embolics: Beyond the Buzz" 📅 Thursday, Oct 8 | ⏰ 7:00 AM #SEAS2026 #IRad
32
We're excited to head to WAIS 2026 in Maui, HI in a few days! Stop by Booth S11 to say hello, meet our team, and learn more about Embrace® HES. Looking forward to some great conversations. #EmbraceHES #InterventionalRadiology #WAIS2026
46
3 vessels. 3 successful embolizations. Enabling definitive hip replacement surgery. 70-year-old with renal cell carcinoma history, treated with Embrace® HES for preoperative embolization of an acetabular lesion. Full case details ⬇️ #EmbraceHES #InterventionalOncology
60
In addition to meeting both primary safety and effectiveness endpoints, the Instylla HES Hypervascular Tumor Study reported several key additional observations. #EmbraceHES #InterventionalRadiology #Embolization
1
2
35
We’re looking forward to being at the Interventional Radiology IEP Residents' & Young Physicians' Conference in Austin this weekend. Visit us at Booth #4 to connect with our team and learn more about Embrace® HES #InterventionalRadiology #InterventionalOncology #EmbraceHES
1
38
Natalie Costello gets a front-row seat to something special: meeting every candidate who walks through Instylla's doors alongside Lindsay Streett, and playing a direct role in shaping our talent and culture. Hear more from Natalie⬇️⬇️
1
28
Embrace the Case. 69M, advanced HCC, prior systemic and locoregional therapy, extrahepatic disease present. Complete Response per mRECIST at 30 and 90 days. No progression. No revascularization. instylla.com/case-studies/tr… #EmbraceHES #HCC #IR
1
1
117
Next up in our spotlight series: Peter Cincotta, Corporate Controller. From day one, he saw a team building something big. Here's what he had to say ⬇️
1
2
30
We are pleased to share that the Embrace HES pivotal study is published in JVIR! doi.org/10.1016/j.jvir.2026.… Please refer to the Embrace HES Instructions for Use (IFU) for complete information regarding indications, contraindications, warnings, precautions, and directions for use.
1
1
34
One year since FDA approval and what a year it's been. From the first commercial case to growing adoption among physicians, it's been a year of momentum and milestones. Thank you to everyone who has been part of the journey. Here's to what's next. #MedicalInnovation #IR #IO
1
1
37
Behind every solution is a person who chose to work on something that changes lives. Today, we start a new series to introduce you to them. First up: Shawna Morris
1
752
Embrace® HES was evaluated against SOC TAE/cTACE in a prospective, randomized, multicenter study. Both primary endpoints met, as determined by an independent core lab and adjudicated by an independent Clinical Events Committee. #EmbraceHES #IR instylla.com/hes-hypervascul…
1
2
42
There was no clinically significant non-target embolization associated with Embrace® HES in 148 treated vessels. Proven in a prospective, randomized, multicenter pivotal trial. #EmbraceHES #IR #Embolization instylla.com/hes-hypervascul…
1
2
41
Embrace the Case. 43F, unresectable liver met from breast cancer. 45% diameter reduction at 90 days. No revascularization. No local tumor progression. Sustained control through 90 days. instylla.com/case-studies/tr… #EmbraceHES #InterventionalOncology #LiverMetastasis #IR
1
1
28
Load more